Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.

Abstract:

BACKGROUND:Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system (CNS) that preferentially targets the spinal cord and optic nerves. Increasing disability is accrued with each inflammatory attack. Disability has been shown to be an independent predictor of poor quality of life in those with NMOSD. Factors associated with increasing disability need further systematic investigation. METHODS:We performed a multi-center retrospective chart analysis of aquaporin-4 (AQP4) seropositive NMOSD patients with a history of myelitis seen at five large referral centers for patients with NMOSD worldwide for whom thorough records including relapse history and corresponding imaging were available. Potential contributors to long-term disability were extracted including demographics, radiographic findings, and clinical characteristics. Multivariable regression modeling was conducted to determine correlates of disability in patients with NMOSD, as measured by the Expanded Disability Status Scale (EDSS). RESULTS:One hundred eighty-two AQP4 seropositive patients (88% female) were included in this analysis. Multiple regression modeling revealed that older age at disease onset, delay in diagnosis/preventive treatment, length of longest acute myelitis lesion and presence of symptomatic brain/brainstem lesions were associated with increased disability when holding other variables constant. CONCLUSION:While age at onset is a factor that cannot be controlled in NMOSD, we can reduce the delay in diagnosis/preventive treatment and reduce future relapses in the brain/brainstem and spinal cord. Delay in diagnosis/preventive treatment and imaging variables that contributed to increased disability support the need for improved measures for early, accurate diagnosis and management of NMOSD, and aggressive treatment of acute relapses.

authors

Mealy MA,Mossburg SE,Kim SH,Messina S,Borisow N,Lopez-Gonzalez R,Ospina JP,Scheel M,Yeshokumar AK,Awad A,Leite MI,Arango JJ,Paul F,Palace J,Kim HJ,Levy M

doi

10.1016/j.msard.2018.12.011

subject

Has Abstract

pub_date

2019-02-01 00:00:00

pages

64-68

eissn

2211-0348

issn

2211-0356

pii

S2211-0348(18)30539-X

journal_volume

28

pub_type

杂志文章,meta分析
  • Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.

    abstract:BACKGROUND:Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with progressive MS (pwPMS). Cladribine has shown efficacy at all stages of MS. Following withdrawal from...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.11.001

    authors: Mao Z,Álvarez-González C,Allen-Philbey K,De Trane S,Yildiz O,Campion T,Adams A,Turner BP,Marta M,Gnanapavan S,Espasandin M,Mathews J,Giovannoni G,Baker D,Schmierer K

    更新日期:2019-01-01 00:00:00

  • Screening of dysphagia by DYMUS (Dysphagia in multiple sclerosis) and SWALQoL (Swallowing quality of life) surveys in patients with multiple sclerosis.

    abstract:BACKGROUND:Dysphagia is a life-threating symptom in patients with multiple sclerosis (MS) because aspiration pneumonia develops as a consequence of swallowing disorders. Dysphagia can be detected by using patient-reported outcome measures in order to prevent complications. OBJECTIVE:To identify the dysphagia prevalenc...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102397

    authors: Tahir E,Kavaz E,Kemal Ö,Şen S,Terzi M

    更新日期:2020-10-01 00:00:00

  • Under-treated depression negatively impacts lifestyle behaviors, participation and health-related quality of life among older people with multiple sclerosis.

    abstract:PURPOSE:To what extent depression may negatively impact successful aging with multiple sclerosis (MS) is not known. We examined the impact of depression/depressive symptoms on lifestyle choices (diet, exercise, smoking and alcohol), participation and health-related quality of life (HRQoL) among older people living with...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.msard.2019.101919

    authors: Ploughman M,Wallack EM,Chatterjee T,Kirkland MC,Curtis ME,Health Lifestyle and Aging with MS Consortium.

    更新日期:2020-05-01 00:00:00

  • Levels of peripheral Th17 cells and serum Th17-related cytokines in patients with multiple sclerosis: A meta-analysis.

    abstract:BACKGROUND:Multiple reports have described the proportion of Th17 cells in peripheral blood and serum levels of Th17-related cytokines in patients with multiple sclerosis (MS). To clarify the status of Th17 cells and Th17-related cytokines in MS patients, we did a meta-analysis of the results published previously to as...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,meta分析,评审

    doi:10.1016/j.msard.2017.09.003

    authors: Li YF,Zhang SX,Ma XW,Xue YL,Gao C,Li XY

    更新日期:2017-11-01 00:00:00

  • Visual pathway involvement in multiple sclerosis: Look straight in the eyes.

    abstract::Visual symptoms are a common clinical manifestation of multiple sclerosis (MS) and are frequently due to acute optic neuritis (ON). However, the entire visual pathway can be involved throughout the disease course. We describe the case of a young MS patient who experienced visual symptoms that were eventually found to ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.08.008

    authors: Gaetani L,Iaccheri B,Cerquaglia A,Gentili L,Fiore T,Di Gregorio M,Mancini A,Calabresi P,Cagini C,Sarchielli P,Di Filippo M

    更新日期:2017-10-01 00:00:00

  • A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19.

    abstract:BACKGROUND:Treatment decisions in patients with multiple sclerosis (MS) during the coronavirus disease 2019 (COVID-19) pandemic are challenging. It is not known whether and how various disease modifying therapies, especially immunosuppressive drugs, affect COVID-19 risk and disease course. METHODS:Case report RESULTS:...

    journal_title:Multiple sclerosis and related disorders

    pub_type:

    doi:10.1016/j.msard.2020.102182

    authors: Valencia-Sanchez C,Wingerchuk DM

    更新日期:2020-07-01 00:00:00

  • Improving MS patients' understanding of treatment risks and benefits in clinical consultations: A randomised crossover trial.

    abstract:BACKGROUND:Multiple Sclerosis (MS) patients find it difficult to understand the complex risk-benefit profiles of disease-modifying drugs. An evidence-based protocol was designed to improve patient's understanding of treatment information: Benefit and Risk Information for Medication in Multiple Sclerosis (BRIMMS). OBJE...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2021.102737

    authors: Reen GK,Silber E,Langdon DW

    更新日期:2021-01-12 00:00:00

  • Antecedent anti-NMDA receptor encephalitis in two patients with multiple sclerosis.

    abstract::Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is an autoimmune disorder characterised by psychiatric symptoms, movement disorder and seizures often evolving into a severe encephalopathy. An overlap has recently been recognised between anti-NMDAR encephalitis and inflammatory demyelinating disorders, particul...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.12.009

    authors: Baheerathan A,Brownlee WJ,Chard DT,Shields K,Gregory R,Trip SA

    更新日期:2017-02-01 00:00:00

  • Mesenchymal stem cells in experimental autoimmune encephalomyelitis model of multiple sclerosis: A systematic review and meta-analysis.

    abstract:BACKGROUND/AIMS:Mesenchymal stem cells (MSCs) transplantation has been considered a possible therapeutic method for Multiple Sclerosis (MS). However, no quantitative data synthesis of MSCs therapy for MS exists. We conducted a systematic review and meta-analysis to evaluate the effects of MSCs in experimental autoimmun...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.102200

    authors: Yanwu Y,Meiling G,Yunxia Z,Qiukui H,Birong D

    更新日期:2020-09-01 00:00:00

  • COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?

    abstract:BACKGROUND:Coronavirus disease 19 (COVID-19) is a novel disease entity that is spreading throughout the world. It has been speculated that patients with comorbidities and elderly patients could be at high risk for respiratory insufficiency and death. Immunosuppression could expose infected patients to even higher risks...

    journal_title:Multiple sclerosis and related disorders

    pub_type:

    doi:10.1016/j.msard.2020.102120

    authors: Novi G,Mikulska M,Briano F,Toscanini F,Tazza F,Uccelli A,Inglese M

    更新日期:2020-07-01 00:00:00

  • Continuous prediction of secondary progression in the individual course of multiple sclerosis.

    abstract:BACKGROUND:Prediction of the course of multiple sclerosis (MS) was traditionally based on features close to onset. OBJECTIVE:To evaluate predictors of the individual risk of secondary progression (SP) identified at any time during relapsing-remitting MS. METHODS:We analysed a database comprising an untreated MS incid...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2014.04.004

    authors: Skoog B,Tedeholm H,Runmarker B,Odén A,Andersen O

    更新日期:2014-09-01 00:00:00

  • Multiple intracranial lesions with lung adenocarcinoma: A rare case of MOG-IgG-associated encephalomyelitis.

    abstract:BACKGROUND:Myelin oligodendrocyte glycoprotein (MOG) is an important marker on the surface of oligodendrocytes and is associated with many demyelinating diseases. Recently, MOG-IgG-associated encephalomyelitis (MOG-EM) has been proposed as a disease entity with a preliminary diagnosis standard. Some patients with lung ...

    journal_title:Multiple sclerosis and related disorders

    pub_type:

    doi:10.1016/j.msard.2020.102064

    authors: Li K,Zhan Y,Shen X

    更新日期:2020-07-01 00:00:00

  • Highly sensitive quantification of optic neuritis intrathecal biomarker CXCL13.

    abstract:BACKGROUND:Elevation of CXCL13, a key regulator of B-cell recruitment in cerebrospinal fluid (CSF) is implicated in multiple sclerosis (MS). OBJECTIVE:to evaluate if measurement of CXCL13 using a highly sensitive assay is of value in acute optic neuritis (ON) patients for the prediction of later MS. METHOD:CXCL13 was...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102281

    authors: Olesen MN,Nilsson AC,Pihl-Jensen G,Soelberg KK,Olsen DA,Brandslund I,Lillevang ST,Madsen JS,Frederiksen JL,Asgari N

    更新日期:2020-09-01 00:00:00

  • Cross-sectional survey of complementary and alternative medicine used in Oregon and Southwest Washington to treat multiple sclerosis: A 17-Year update.

    abstract:BACKGROUND:In 2001, we conducted a survey on use of complementary and alternative medicine (CAM) in people with multiple sclerosis (pwMS) in Oregon and Southwest Washington to treat their disease. OBJECTIVES, METHODS:In 2018, we administered a revised survey in the same region to describe updated patterns of CAM use i...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102041

    authors: Silbermann E,Senders A,Wooliscroft L,Rice J,Cameron M,Waslo C,Orban A,Chase E,Yadav V,Bourdette D,Spain RI

    更新日期:2020-06-01 00:00:00

  • Evaluation of types of psychological disorders in patients with neuromyelitis optica spectrum disorder (NMOSD).

    abstract:BACKGROUND:Neuromyelitis Optica Spectrum Disorder (NMOSD), commonly characterized by affecting optic nerves and spinal cord can be regarded as one of uncommon diseases of the central nervous system. Although the evidence presented in the literature supports cognitive impairments, psychological aspects of the disease an...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102128

    authors: Ebadi Z,Saeedi R,Hashemi SN,Gheini MR,Sahraian MA,Naser Moghadasi A

    更新日期:2020-07-01 00:00:00

  • CNS demyelination during tofacitinib therapy: First report.

    abstract::Iatrogenic demyelination is a distinct clinical subtype of central nervous system inflammatory disorders. The Janus kinase inhibitor, tofacitinib, is an oral disease-modifying antirheumatic drug that has shown contradictory effects on multiple sclerosis in animal models. In this report, we describe a novel case of rev...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 信件

    doi:10.1016/j.msard.2020.102568

    authors: Massoud F,Ismail II,Al-Hashel JY,Abboud H

    更新日期:2020-11-01 00:00:00

  • Development of a brief clinician-reported outcome measure of multiple sclerosis signs and symptoms: The Clinician Rating of Multiple Sclerosis (CRoMS).

    abstract:OBJECTIVE:No available assessment tool offers a brief and psychometrically sound way for clinicians to quantify assessment of MS in a typical office visit. The objective of this study was to develop a brief clinician-reported outcome measure of MS signs and symptoms to standardize and quantify assessments that occur du...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.06.024

    authors: Matza LS,Stewart KD,Phillips G,Delio P,Naismith RT

    更新日期:2019-10-01 00:00:00

  • Longitudinal study of retinal nerve fiber layer thickness changes in a multiple sclerosis patients cohort: A long term 5 year follow-up.

    abstract:PURPOSE:To analyze the changes in retinal nerve fiber layer (RNFL) in eyes with and without prior history of optic neuritis (ON) of patients with multiple sclerosis (MS) after a 5-year time period (2010-2015) using optical coherence tomography. METHODS:The RNFL thickness of 114 eyes of 57 MS patients and 40 eyes of 20...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2017.11.017

    authors: Abalo-Lojo JM,Treus A,Arias M,Gómez-Ulla F,Gonzalez F

    更新日期:2018-01-01 00:00:00

  • An extremely aggressive case of Marburg's disease treated with high dose cyclophosphamide. A case report.

    abstract:BACKGROUND:The acute, fulminant type of Multiple Sclerosis (MS), known as Marburg Disease, has been shown to have poor response to conventional acute treatments typically used for demyelinating diseases. METHODS:We report a 20 y/o postpartum female who was consulted to the Neurology service given findings of subacute ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.03.014

    authors: Avila-Ornelas J,Labat E,Alfonso G,Serrano C,Fiorito F

    更新日期:2019-06-01 00:00:00

  • Treating acute ischemic stroke in a patient with multiple sclerosis: A challenging issue.

    abstract::Multiple sclerosis (MS) is a chronic disease characterized by inflammation, demyelination and neurodegeneration in the central nervous system. Recent studies suggested that patients with MS might have a greater risk of ischaemic stroke (IS). IS treatment with intravenous alteplase (IVA) in MS has rarely been reported....

    journal_title:Multiple sclerosis and related disorders

    pub_type:

    doi:10.1016/j.msard.2020.101962

    authors: de Falco A,De Simone M,d'Onofrio F,Spitaleri D,de Falco FA

    更新日期:2020-05-01 00:00:00

  • Peripapillary retinal nerve fiber layer thickness measured by optical coherence tomography in different clinical subtypes of multiple sclerosis.

    abstract:BACKGROUND:Multiple sclerosis (MS) is a chronic inflammatory demyelinating autoimmune disease of the central nervous system (CNS) with axonal degeneration as major determinant of neurological disability. Assessment of unmyelinated retinal nerve fibers using optical coherence tomography (OCT) may be useful for diagnosin...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.11.003

    authors: Jankowska-Lech I,Wasyluk J,Palasik W,Terelak-Borys B,Grabska-Liberek I

    更新日期:2019-01-01 00:00:00

  • Myelorradiculitis due to Varicella Zoster (Elsberg syndrome) as the first symptom of HIV in a patient with Crohn's disease in use of Infliximab.

    abstract::Elsberg syndrome (ES) refers to the combination of myelitis and lumbosacral radiculitis associated with infection caused by the virus of the Herpesviridae family. We present a case of a 52-year-old man with a 9 months diagnosis of Crohn's disease, in use of infliximab with good disease control, complaining of 2 months...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 信件

    doi:10.1016/j.msard.2020.102643

    authors: Santos DH,Carneiro de Oliveira RM,Junior WRF,Olivetti BC

    更新日期:2020-11-25 00:00:00

  • The case for vitamin D supplementation in multiple sclerosis.

    abstract:INTRODUCTION:Given that vitamin D has a role in immunomodulation, and its levels appear to correlate with the development of Multiple Sclerosis (MS), it is conceivable that vitamin D may also influence disease activity in MS patients. In this regard, we conducted a systematic review investigating the evidence for: (1) ...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2012.12.008

    authors: Ganesh A,Apel S,Metz L,Patten S

    更新日期:2013-10-01 00:00:00

  • Temporal evolution of acute multiple sclerosis lesions on serial sodium (23Na) MRI.

    abstract:BACKGROUND:Several studies have reported the characteristics of acute multiple sclerosis (MS) lesions on diffusion-weighted magnetic resonance imaging (DWI MRI). Current publications reported a transient reduction of the apparent diffusion coefficient (ADC) delineating an early phase of lesion evolution, before increas...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2019.01.027

    authors: Eisele P,Konstandin S,Szabo K,Ebert A,Roßmanith C,Paschke N,Kerschensteiner M,Platten M,Schoenberg SO,Schad LR,Gass A

    更新日期:2019-04-01 00:00:00

  • The epidemiology of comorbidities among multiple sclerosis patients in northeastern Poland.

    abstract:BACKGROUND:To determine and compare comorbidity levels in the multiple sclerosis (MS) population in Poland using a matched cohort from the general population. METHODS:We compared our database (standardized medical histories and medical records) from a MS center at the Department of Neurology, Medical University of Bia...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102051

    authors: Kapica-Topczewska K,Tarasiuk J,Chorąży M,Czarnowska A,Brola W,Szczepański M,Kochanowicz J,Kułakowska A

    更新日期:2020-06-01 00:00:00

  • Chronic lung disease and multiple sclerosis: Incidence, prevalence, and temporal trends.

    abstract:OBJECTIVES:We aimed to estimate the incidence and prevalence of chronic lung disease (CLD), including asthma and chronic obstructive pulmonary disease, in the MS population versus a matched cohort from the general population. METHODS:We used population-based administrative data from four Canadian provinces to identify...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2016.05.009

    authors: Marrie RA,Patten S,Tremlett H,Svenson LW,Wolfson C,Yu BN,Elliott L,Profetto-McGrath J,Warren S,Leung S,Jette N,Bhan V,Fisk JD

    更新日期:2016-07-01 00:00:00

  • Impact of multiple sclerosis relapse: The NARCOMS participant perspective.

    abstract::Acute relapses continue to be a significant aspect of multiple sclerosis (MS) on both the epidemiologic level and the individual patient level. Past work demonstrates residual disability from relapses as well as high patient-reported rates of ineffective relapse treatment. To better characterize the impact of MS relap...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2015.03.005

    authors: Nickerson M,Cofield SS,Tyry T,Salter AR,Cutter GR,Marrie RA

    更新日期:2015-05-01 00:00:00

  • Forkhead box C1 gene variant causing glaucoma and small vessel angiopathy can mimic multiple sclerosis.

    abstract::A 34-year old Caucasian female was initially diagnosed with multiple small-vessel strokes at age 20 years which were etiologically classified as secondary to anti-phospholipid antibody syndrome (APS) although she had no history or laboratory data to suggest APS. Based on her MRI of brain findings, one of her neurologi...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2018.04.004

    authors: Avasarala JR,Jones JR,Rogers CR

    更新日期:2018-05-01 00:00:00

  • Functional recovery in multiple sclerosis patients undergoing rehabilitation programs is associated with plasma levels of hemostasis inhibitors.

    abstract:BACKGROUND:Increasing evidence for contribution of hemostasis components in multiple sclerosis (MS) has been reported. Hemostasis protein inhibitors display key regulatory roles, extending to regulation of innate immune response and inflammation, and promotion of blood-brain barrier integrity. Whereas the effects on he...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章

    doi:10.1016/j.msard.2020.102319

    authors: Ziliotto N,Lamberti N,Manfredini F,Straudi S,Baroni M,Tisato V,Carantoni M,Secchiero P,Basaglia N,Marchetti G,Bernardi F

    更新日期:2020-09-01 00:00:00

  • The ocrelizumab phase II extension trial suggests the potential to improve the risk: Benefit balance in multiple sclerosis.

    abstract:OBJECTIVE:Ocrelizumab inhibits relapsing multiple sclerosis when administered every six months. Based on potential similar memory B cell depletion mechanisms with cladribine and alemtuzumab, we hypothesised that CD20-depletion of B cells by ocrelizumab may exhibit a duration of response exceeding the current licenced t...

    journal_title:Multiple sclerosis and related disorders

    pub_type: 杂志文章,评审

    doi:10.1016/j.msard.2020.102279

    authors: Baker D,Pryce G,James LK,Marta M,Schmierer K

    更新日期:2020-09-01 00:00:00